The classification of MDS: From FAB to WHO and beyond

Leukemia Research

Volumn 36, Issue 12, 2012, Pages 1453-1458

  Vardiman, James ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

FAB classification; Myelodysplastic syndrome (MDS); WHO classification

Indexed keywords

ALKYLATING AGENT; CYTOTOXIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; CHROMOSOME ANALYSIS; CHROMOSOME DELETION 5; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL FEATURE; DISEASE CLASSIFICATION; DISEASE COURSE; GENETIC DISORDER; GENETICS; HEALTH CARE ORGANIZATION; HISTOPATHOLOGY; HUMAN; MEDICAL INFORMATION; MYELODYSPLASTIC SYNDROME; PATIENT CARE; PRACTICE GUIDELINE; PRELEUKEMIA; PRIORITY JOURNAL; PROGNOSIS; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH MULTILINEAGE DYSPLASIA; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REVIEW; SOMATIC MUTATION; WORLD HEALTH ORGANIZATION;

BLOOD CELLS; BONE MARROW; CHROMOSOME ABERRATIONS; GUIDELINES AS TOPIC; HUMANS; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TERMINOLOGY AS TOPIC; WORLD HEALTH ORGANIZATION;

EID: 84868193421     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.08.008     Document Type: Review

References (60)

1. Bennett J.M., Catovsky D., Daniel M.T., et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976, 33:451-458.
2. Luzzatto A. Sull anemia grave megaloblastica senza reporto ematolgico corrispondenta (anemia pseudoaplastica). Riv Veneta di sc Med Venezia 1907, 47:193-212.
3. Hamilton-Paterson J.L. Pre-leukaemic anaemia. Acta Haematol 1949, 2:309-316.
4. Block M., Jacobson L.O., Bethard W.F. Preleukemic acute human leukemia. J Am Med Assoc 1953, 152:1018-1028.
5. Rowley J.D., Blaisdell R.K., Jacobson L.O. Chromosome studies in preleukemia. I. Aneuploidy of group C chromosomes in three patients. Blood 1966, 27:782-799.
6. Saarni M.I., Linman J.W. Preleukemia. The hematologic syndrome preceding acute leukemia. Am J Med 1973, 55:38-48.
7. Bennett J.M., Catovsky D., Daniel M.T., et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982, 51:189-199.
8. Vallespi T., Torrabadella M., Julia A., et al. Myelodysplastic syndromes: a study of 101 cases according to the FAB classification. Br J Haematol 1985, 61:83-92.
9. Kerkhofs H., Hermans J., Haak H.L., Leeksma C.H. Utility of the FAB classification for myelodysplastic syndromes: investigation of prognostic factors in 237 cases. Br J Haematol 1987, 65:73-81.
10. Greenberg P., Cox C., LeBeau M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
11. Harris N.L., Jaffe E.S., Diebold J., et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting - Airlie House, Virginia, November 1997. J Clin Oncol 1999, 17:3835-3849.
12. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues 2001, IARC, Lyon. E.S. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman (Eds.).
13. Vardiman J.W., Harris N.L., Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002, 100:2292-2302.
14. Mufti G.J., Stevens J.R., Oscier D.G., Hamblin T.J., Machin D. Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 1985, 59:425-433.
15. Sanz G.F., Sanz M.A., Vallespi T., et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 1989, 74:395-408.
16. Morel P., Hebbar M., Lai J.L., et al. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia 1993, 7:1315-1323.
17. Gattermann N., Aul C., Schneider W. Two types of acquired idiopathic sideroblastic anaemia (AISA). Br J Haematol 1990, 74:45-52.
18. Rosati S., Mick R., Xu F., et al. Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome. Leukemia 1996, 10:20-26.
19. Germing U., Gattermann N., Aivado M., Hildebrandt B., Aul C. Two types of acquired idiopathic sideroblastic anaemia (AISA): a time-tested distinction. Br J Haematol 2000, 108:724-728.
20. Estey E., Pierce S., Kantarjian H., et al. Treatment of myelodysplastic syndromes with AML-type chemotherapy. Leuk Lymphoma 1993, 11(Suppl. 2):59-63.
21. Bernstein S.H., Brunetto V.L., Davey F.R., et al. Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a Cancer and Leukemia Group B Study. J Clin Oncol 1996, 14:2486-2494.
22. Vardiman J.W., Golomb H.M., Rowley J.D., Variakojis D. Acute nonlymphocytic leukemia in malignant lymphoma: a morphologic study. Cancer 1978, 42:229-242.
23. Michels S.D., McKenna R.W., Arthur D.C., Brunning R.D. Therapy-related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphologic study of 65 cases. Blood 1985, 65:1364-1372.
24. Smith S.M., Le Beau M.M., Huo D., et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 2003, 102:43-52.
25. Michaux J.L., Martiat P. Chronic myelomonocytic leukaemia (CMML)-a myelodysplastic or myeloproliferative syndrome?. Leuk Lymphoma 1993, 9:35-41.
26. Germing U., Gattermann N., Minning H., Heyll A., Aul C. Problems in the classification of CMML-dysplastic versus proliferative type. Leuk Res 1998, 22:871-878.
27. Brunning R.S.O.A., Germing U., Le Beau M., Porwit A., Baumann I., Vardiman J.W., et al. Myelodysplastic syndromes/neoplasms, overview. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, International Agency for Research on Cancer, Lyon. fourth ed. S. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein (Eds.).
28. Germing U., Gattermann N., Strupp C., Aivado M., Aul C. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res 2000, 24:983-992.
29. Howe R.B., Porwit-MacDonald A., Wanat R., Tehranchi R., Hellstrom-Lindberg E. The WHO classification of MDS does make a difference. Blood 2004, 103:3265-3270.
30. Cazzola M., Della Porta M.G., Travaglino E., Malcovati L. Classification and prognostic evaluation of myelodysplastic syndromes. Semin Oncol 2011, 38:627-634.
31. Strupp C., Gattermann N., Giagounidis A., et al. Refractory anemia with excess of blasts in transformation: analysis of reclassification according to the WHO proposals. Leuk Res 2003, 27:397-404.
32. Orazi A., Bennett J.M., Germing U., Brunning R.D., Bain B.J., Thiele J. Chronic myelomonocytic leukaemia. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008, 76-79. IARC, Lyon. S.H. Swerdlow, E. Campo, E.S. Jaffe (Eds.).
33. Haferlach T., Schoch C., Loffler H., et al. Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies. J Clin Oncol 2003, 21:256-265.
34. Wandt H., Schakel U., Kroschinsky F., et al. MLD according to the WHO classification in AML has no correlation with age and no independent prognostic relevance as analyzed in 1766 patients. Blood 2008, 111:1855-1861.
35. Weinberg O.K., Seetharam M., Ren L., et al. Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system. Blood 2009, 113:1906-1908.
36. Arber D.A., Brunning R.D., Orazi A., Bain B.J., Porwit A., Vardiman J.W., et al. Acute myeloid leukaemia with myelodysplasia-related changes. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, 124-126. International Agency for Research on Cancer, Lyon. fourth ed. S. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein (Eds.).
37. Andersen M.K., Larson R.A., Mauritzson N., Schnittger S., Jhanwar S.C., Pedersen-Bjergaard J. Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer 2002, 33:395-400.
38. Bloomfield C.D., Archer K.J., Mrozek K., et al. 11q23 balanced chromosome aberrations in treatment-related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer 2002, 33:362-378.
39. Rowley J.D., Olney H.J. International workshop on the relationship of prior therapy to balanced chromosome aberrations in therapy-related myelodysplastic syndromes and acute leukemia: overview report. Genes Chromosomes Cancer 2002, 33:331-345.
40. Singh Z.N., Huo D., Anastasi J., et al. Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant. Am J Clin Pathol 2007, 127:197-205.
41. Godley L.A., Cunningham J., Dolan M.E., et al. An integrated genomic approach to the assessment and treatment of acute myeloid leukemia. Semin Oncol 2011, 38:215-224.
42. Best T., Li D., Skol A.D., et al. Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma. Nat Med 2011, 17:941-943.
43. Bennett J.M., Catovsky D., Daniel M.T., et al. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. Br J Haematol 1994, 87:746-754.
44. Germing U., Strupp C., Knipp S., et al. Chronic myelomonocytic leukemia in the light of the WHO proposals. Haematologica 2007, 92:974-977.
45. Harrington A., Olteanu H., Kroft S. The specificity of immunophenotypic alterations in blasts in nonacute myeloid disorders. Am J Clin Pathol 2010, 134:749-761.
46. Porwit A. Role of flow cytometry in diagnostics of myelodysplastic syndromes-beyond the WHO 2008 classification. Semin Diagn Pathol 2011, 28:273-282.
47. Gelsi-Boyer V., Trouplin V., Adelaide J., et al. Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes. BMC Cancer 2008, 8:299.
48. Ricci C., Fermo E., Corti S., et al. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant. Clin Cancer Res 2010, 16:2246-2256.
49. Kohlmann A., Grossmann V., Klein H.U., et al. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol 2010, 28:3858-4386.
50. Bacher U., Haferlach T., Schnittger S., Kreipe H., Kroger N. Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia. Br J Haematol 2011, 153:149-167.
51. Jankowska A.M., Makishima H., Tiu R.V., et al. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood 2012, 118:3932-3941.
52. Kosmider O., Gelsi-Boyer V., Ciudad M., et al. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica 2009, 94:1676-1681.
53. Van den Berghe H., Cassiman J.J., David G., Fryns J.P., Michaux J.L., Sokal G. Distinct haematological disorder with deletion of long arm of no. 5 chromosome. Nature 1974, 251:437-438.
54. Boultwood J., Lewis S., Wainscoat J.S. The 5q-syndrome. Blood 1994, 84:3253-3260.
55. Bacher U., Haferlach T., Kern W., Haferlach C., Schnittger S. A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. Haematologica 2007, 92:744-752.
56. Rocquain J., Carbuccia N., Trouplin V., et al. Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer 2010, 10:401.
57. Bejar R., Stevenson K., Abdel-Wahab O., et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011, 364:2496-2506.
58. Papaemmanuil E., Cazzola M., Boultwood J., et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011, 365:1384-1395.
59. Shih A.H., Levine R.L. Molecular biology of myelodysplastic syndromes. Semin Oncol 2011, 38:613-620.
60. Makishima H., Visconte V., Sakaguchi H., et al. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood 2012, 119:3203-3210.